Changes to the Code
S. 3302 · Mikaela Naylon Give Kids a Chance Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 355c Research into pediatric uses for drugs and biological products
6 changes the bill asks for here, 3 carried out
- Carried out:
by redesignating subparagraphs (B) and (C) as subparagraphs (C) and (D), respectively; and
The section already has a provision under this letter or number, so it would have two.
- Carried out:
by striking subparagraph (A) and inserting the following:
(A) In general.— For purposes of paragraph (1)(B), the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of— (i) the drug or biological product for which the application referred to in such paragraph is submitted; or (ii) such …
- Carried out:
Section 505B(e)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(e)(1)) is amended by adding at the end the following:
The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).
. - Not carried out:
Section 505B(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355c(a)(1)) is amended by adding at the end the following:
(C) Rule of construction.— No application that is subject to the requirements of subparagraph (B) shall be subject to the requirements of subparagraph (A), and no application (or supplement to an application) that is subject to the requirements of subparagraph (A) shall be …
The law already reads this way: § 355c(a)(1)(C) is already as the bill would have it.
Technical detail
already there: /us/usc/t21/s355c/a/1/C reads as the bill would have it - Not carried out:
in paragraph (3)(C), as redesignated by paragraph (1)(A) of this subsection, by striking
investigations described in this paragraph
and insertinginvestigations referred to in subparagraph (A)
; and“investigations described in this paragraph” isn't in § 355c(a)(3)(C) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“investigations described in this paragraph” not found in /us/usc/t21/s355c/a/3/C - Not carried out:
in paragraph (3)(D), as redesignated by paragraph (1)(A) of this subsection, by striking
the assessments under paragraph (2)(B)
and insertingthe assessments required under paragraph (1)(A)
.“the assessments under paragraph (2)(B)” isn't in § 355c(a)(3)(D) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“the assessments under paragraph (2)(B)” not found in /us/usc/t21/s355c/a/3/D~2
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
1 of the 6 changes this bill asks for here is already in the law as it stands, and was not made a second time. The bill, or another making the same changes, has probably become law since.
§ 355c(a)New drugs and biological products(2)–(4)
Start of § 355c to (a)(2)(B)(ii) unchanged ·
(iii) Information on extrapolation A brief documentation of the scientific data supporting the conclusion under clauses (i) and (ii) shall be included in any pertinent reviews for the application under section 355 of this title or section 262 of title 42.
(3) 1 Molecularly targeted pediatric cancer investigation
(A) In general[inserted: .—] For purposes of paragraph (1)(B), the investigation described in this paragraph is a molecularly targeted pediatric cancer investigation of—
(i) the drug or biological product for which the application referred to in such paragraph is submitted; or
(ii) such drug or biological product used in combination with—
(I) an active ingredient of a drug or biological product—
(aa) for which an approved application under section [struck: 355][inserted: 505](j) under this [struck: title][inserted: Act] or under section [struck: 262][inserted: 351](k) of [struck: title][inserted: the] [struck: 42][inserted: Public] [inserted: Health Service Act ]is in effect; and
(bb) that is determined by the Secretary, after consultation with the applicant, to be part of the standard of care for treating a pediatric cancer; or
(II) an active ingredient of a drug or biological product—
(aa) for which an approved application under section [struck: 355][inserted: 505](b) of this [struck: title][inserted: Act] or section [struck: 262][inserted: 351](a) of [struck: title][inserted: the] [struck: 42][inserted: Public] [inserted: Health Service Act ]to treat an adult cancer is in effect and is held by the same person submitting the application under paragraph (1)(B); and
(bb) that is directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer.
(B) [inserted: Additional requirements.—]
(i) [inserted: Design of investigation.—] [inserted: A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling.]
(ii) [inserted: Limitation.—] [inserted: An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either—]
(I) [inserted: a single new active ingredient; or]
(II) [inserted: more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient is in a drug product that has been previously approved to treat an adult cancer.]
(iii) [inserted: Results of already-completed preclinical studies of application drug.—] [inserted: With respect to an investigation required pursuant to paragraph (1)(B), the Secretary may require the results of any completed preclinical studies relevant to the initial pediatric study plan be submitted to the Secretary at the same time that the initial pediatric study plan required under subsection (e)(1) is submitted.]
(iv) [inserted: Rule of construction regarding inactive ingredients.—] [inserted: With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination.]
[struck: (B)] [inserted: (C)] Additional requirements
(i) Design of investigation A molecularly targeted pediatric cancer investigation referred to in subparagraph (A) shall be designed to yield clinically meaningful pediatric study data that is gathered using appropriate formulations for each age group for which the study is required, regarding dosing, safety, and preliminary efficacy to inform potential pediatric labeling.
(ii) Limitation An investigation described in subparagraph (A)(ii) may be required only if the drug or biological product for which the application referred to in paragraph (1)(B) contains either—
(I) a single new active ingredient; or
(II) more than one active ingredient, if an application for the combination of active ingredients has not previously been approved but each active ingredient is in a drug product that has been previously approved to treat an adult cancer.
(iii) Results of already-completed preclinical studies of application drug With respect to an investigation required pursuant to paragraph (1)(B), the Secretary may require the results of any completed preclinical studies relevant to the initial pediatric study plan be submitted to the Secretary at the same time that the initial pediatric study plan required under subsection (e)(1) is submitted.
(iv) Rule of construction regarding inactive ingredients With respect to a combination of active ingredients referred to in subparagraph (A)(ii), such subparagraph shall not be construed as addressing the use of inactive ingredients with such combination.
[struck: (C)] [inserted: (D)] Extrapolation of data Paragraph (2)(B) shall apply to investigations referred to in subparagraph (A) to the same extent and in the same manner as paragraph (2)(B) applies with respect to the assessments required under paragraph (1)(A).
(D) Deferrals and waivers Deferrals and waivers under paragraphs (4) and (5) shall apply to investigations described in this paragraph to the same extent and in the same manner as such deferrals and waivers apply with respect to the assessments required under paragraph (1)(A).
(4) Deferral
§ 355c(d)–(e)
(a)(4)(A)–(d)(4)(B) unchanged ·
(C) after reviewing such written response, determine whether the person demonstrated a lack of due diligence in satisfying such requirement.
(e) Pediatric study plans
(1) In general An applicant subject to subsection (a) shall submit to the Secretary an initial pediatric study plan prior to the submission of the assessments described under subsection (a)(2) or the investigation described in subsection (a)(3). The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).1[inserted: The Secretary shall determine whether subparagraph (A) or (B) of subsection (a)(1) applies with respect to an application before the date on which the applicant is required to submit the initial pediatric study plan under paragraph (2)(A).]
(2) Timing; content; meetings
(A) Timing An applicant shall submit the initial pediatric study plan under paragraph (1)—
Rest of § 355c unchanged ·
21 U.S.C. § 360ff Priority review to encourage treatments for rare pediatric diseases
The bill's words for this section
- Not carried out:
Section 529(b)(5) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(b)(5)) is amended by striking
December 20, 2024, unless
and all that follows through the period at the end and insertingSeptember 30, 2030.
.“December 20, 2024, unless” isn't in § 360ff(b)(5) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“December 20, 2024, unless” not found in /us/usc/t21/s360ff/b/5